Zepbound Outperforms CagriSema in Head to Head Phase III Obesity Trial Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination New Developments in Pharmacological Treatment of Obesity and Type 2 DiabetesBeyond and within GLP 1 Receptor Agonists Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine